TY - JOUR
T1 - An updated report on the incidence and epidemiological trends of keratinocyte cancers in the United Kingdom 2013-2018
AU - Kwiatkowska, M.
AU - Ahmed, S.
AU - Ardern-Jones, M.
AU - Bhatti, L. A.
AU - Bleiker, T. O.
AU - Gavin, A.
AU - Hussain, S.
AU - Huws, D. W.
AU - Irvine, L.
AU - Langan, S. M.
AU - Millington, G. W. M.
AU - Mitchell, H.
AU - Murphy, R.
AU - Paley, L.
AU - Proby, C. M.
AU - Thomson, C. S.
AU - Thomas, R.
AU - Turner, C.
AU - Vernon, S.
AU - Venables, Z. C.
N1 - funding Information:
This work was supported by a Rowling Scholar fellowship (Anne Rowling Regenerative Neurology Clinic, University of Edinburgh) and a Doreen Maguire bursary (Department of Palliative Medicine, University of Edinburgh) (P.F.); the Medical Research Council of Great Britain and Northern Ireland, and Wellcome (IT and Wellcome Centre for Integrative Neuroimaging, FMRIB, University of Oxford). C.J.W. was supported in this work by National Health Service Lothian via the Edinburgh Clinical Trials Unit.
© 2021 The Authors. Skin Health and Disease published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
PY - 2021/12
Y1 - 2021/12
N2 - Introduction: The most common cancers in the UK are keratinocyte cancers (KCs): the combined term for basal cell carcinomas (BCCs) and cutaneous squamous cell carcinomas (cSCCs). Registration of KC is challenging due to high numbers and multiplicity of tumours per person.Methods: We provide an updated report on the descriptive epidemiology of trends in KC incidence for the resident populations of UK countries (England, Northern Ireland, Scotland and Wales) using population-based cancer registry and pathology report data, 2013-18.Results: Substantial increases in cSCC incidence in England, Scotland and Northern Ireland can be detected for the period of 2013-18, and the incidence of cSCC also increased in Wales from 2016 to 2018. In contrast, however, the pattern of annual change in the incidence of BCC across the nations differs. In England, the incidence of BCC declined slightly from 2016 to 2018, however, the overall trend across 2013-18 is not statistically significant. In Scotland, the incidence of BCC shows some variability, declining in 2017 before increasing in 2018, and the overall trend across 2013-18 was also not statistically significant. In Northern Ireland, the incidence of BCC increased significantly over the study period, and in Wales, the incidence of BCC increased from 2016 to 2018. One in five people will develop non-melanoma skin cancers (NMSC) in their lifetime in England. This estimate is much higher than the lifetime risk of melanoma (1 in 36 males and 1 in 47 females born after 1960 in the UK), which further highlights the burden of the disease and importance of early prevention strategies.Conclusions: We highlight how common these tumours are by publishing the first ever lifetime incidence of NMSC. Additionally, the first time reporting of the age standardised incidence of KC in Wales further confirms the scale of the disease burden posed by these cancers in the UK. With approximately one in five people developing NMSC in their lifetime, optimisation of skin cancer prevention, management and research are essential.
AB - Introduction: The most common cancers in the UK are keratinocyte cancers (KCs): the combined term for basal cell carcinomas (BCCs) and cutaneous squamous cell carcinomas (cSCCs). Registration of KC is challenging due to high numbers and multiplicity of tumours per person.Methods: We provide an updated report on the descriptive epidemiology of trends in KC incidence for the resident populations of UK countries (England, Northern Ireland, Scotland and Wales) using population-based cancer registry and pathology report data, 2013-18.Results: Substantial increases in cSCC incidence in England, Scotland and Northern Ireland can be detected for the period of 2013-18, and the incidence of cSCC also increased in Wales from 2016 to 2018. In contrast, however, the pattern of annual change in the incidence of BCC across the nations differs. In England, the incidence of BCC declined slightly from 2016 to 2018, however, the overall trend across 2013-18 is not statistically significant. In Scotland, the incidence of BCC shows some variability, declining in 2017 before increasing in 2018, and the overall trend across 2013-18 was also not statistically significant. In Northern Ireland, the incidence of BCC increased significantly over the study period, and in Wales, the incidence of BCC increased from 2016 to 2018. One in five people will develop non-melanoma skin cancers (NMSC) in their lifetime in England. This estimate is much higher than the lifetime risk of melanoma (1 in 36 males and 1 in 47 females born after 1960 in the UK), which further highlights the burden of the disease and importance of early prevention strategies.Conclusions: We highlight how common these tumours are by publishing the first ever lifetime incidence of NMSC. Additionally, the first time reporting of the age standardised incidence of KC in Wales further confirms the scale of the disease burden posed by these cancers in the UK. With approximately one in five people developing NMSC in their lifetime, optimisation of skin cancer prevention, management and research are essential.
U2 - 10.1002/ski2.61
DO - 10.1002/ski2.61
M3 - Article
C2 - 35663774
SN - 2690-442X
VL - 1
JO - Skin health and disease
JF - Skin health and disease
IS - 4
M1 - e61
ER -
